基本信息
浏览量:226
职业迁徙
个人简介
Vincent Gnanapragasam holds a Personal Readership in Urology in the University of Cambridge and is Honorary Consultant Urologist at Addenbrooke’s Hospital, Cambridge. He graduated from Newcastle University and following basic surgical training, was one of the first trainees to be funded through a Cancer Research UK PhD for Clinicians and one of the first recipients of a CRUK Clinician Scientist Fellowship given to a surgeon.
Vincent’s research has covered the full spectrum of basic science, translational, clinical and epidemiological disciplines in prostate cancer. His early laboratory work as group leader led to novel discoveries into the role of endogenous signalling regulators (SEF/SPRED) in prostate cancer development and mechanistic insights into treatment resistance from growth factor inhibitors.
More recently, he has developed novel, more accurate, prognostic prediction models for both group stratified cohorts Cambridge Prognostic Groups and for individualised prediction Predict Prostate and pioneered risk stratified pathways for active surveillance follow up. These models have been shown to outperform current guideline endorsed risk models and have been adopted into local and regional guidelines. Predict prostate is the only decision aid endorsed by the UK NICE National Guidelines on prostate cancer.
He is Chief Investigator of the DIAMOND prostate cancer and urological biobank, which hold over 3000 bio-samples, tissue and annotated clinical data. He is CI of the TAPS01 study, NIHRi4i funded CAMPROBE study (based on his invention of a new simple device for infection free prostate biopsies), national Predict Prostate patient RCT and multi-centre PRIM biomarker-imaging cancer detection study. His work has been cited in prostate cancer guidelines by NICE and the European Association of Urology. To further interdisciplinary research in prostate cancer he established the Translational Prostate Cancer Group (TPCG) in Cambridge with colleagues from urology, oncology, radiology, pathology and basic science. The TPCG have so far collaborated on >50 peer reviewed papers with a combined grant income of >£3M. He has also established links with STEM scientists to develop biosensors for cancer detection across different platforms.
He is a member of the UK ICGC prostate group and on the clinical steering committee of the International Pan Prostate Cancer Collaborative. He is a founder member of the International GAP3 Active Surveillance consortium. To date he has raised over £4M in personal research funding covering basic, translational and clinical trials research, over £5M as co-investigator and published over 140 peer reviewed papers. He is also joint applicant on research collaboratives that have secured over £70M in funding.
His current clinical practice is in precision diagnostics and personalised risk-based management of prostate cancer. He has introduced practice changing innovations including risk-based stratification and tailored surveillance which has standardised patient care and significantly reduced over-treatment. More recently, with colleagues from the TPCG, he has established a platform for Integrated Genomics and Clinical Profiling to explore the potential for targeted adjuvant therapies to improve primary cure rates in poor prognosis prostate cancer.
In the University of Cambridge, he leads the University Academic Urology Group and established the Cambridge Urology Translational Research and Clinical Trials office which has recruited >1600 patients to various NIHR and portfolio urology trials. He is also clinical directorate lead for urology research. He holds patents and has won numerous prizes for research, including the CE Alken prize, Urological Research Society Medial, Hunterian Professorship and is the recipient of a University of Cambridge Vice Chancellors Award for Research Impact (Established Researcher). He is also Visiting Professor at Anglia Ruskin University.
Vincent’s research has covered the full spectrum of basic science, translational, clinical and epidemiological disciplines in prostate cancer. His early laboratory work as group leader led to novel discoveries into the role of endogenous signalling regulators (SEF/SPRED) in prostate cancer development and mechanistic insights into treatment resistance from growth factor inhibitors.
More recently, he has developed novel, more accurate, prognostic prediction models for both group stratified cohorts Cambridge Prognostic Groups and for individualised prediction Predict Prostate and pioneered risk stratified pathways for active surveillance follow up. These models have been shown to outperform current guideline endorsed risk models and have been adopted into local and regional guidelines. Predict prostate is the only decision aid endorsed by the UK NICE National Guidelines on prostate cancer.
He is Chief Investigator of the DIAMOND prostate cancer and urological biobank, which hold over 3000 bio-samples, tissue and annotated clinical data. He is CI of the TAPS01 study, NIHRi4i funded CAMPROBE study (based on his invention of a new simple device for infection free prostate biopsies), national Predict Prostate patient RCT and multi-centre PRIM biomarker-imaging cancer detection study. His work has been cited in prostate cancer guidelines by NICE and the European Association of Urology. To further interdisciplinary research in prostate cancer he established the Translational Prostate Cancer Group (TPCG) in Cambridge with colleagues from urology, oncology, radiology, pathology and basic science. The TPCG have so far collaborated on >50 peer reviewed papers with a combined grant income of >£3M. He has also established links with STEM scientists to develop biosensors for cancer detection across different platforms.
He is a member of the UK ICGC prostate group and on the clinical steering committee of the International Pan Prostate Cancer Collaborative. He is a founder member of the International GAP3 Active Surveillance consortium. To date he has raised over £4M in personal research funding covering basic, translational and clinical trials research, over £5M as co-investigator and published over 140 peer reviewed papers. He is also joint applicant on research collaboratives that have secured over £70M in funding.
His current clinical practice is in precision diagnostics and personalised risk-based management of prostate cancer. He has introduced practice changing innovations including risk-based stratification and tailored surveillance which has standardised patient care and significantly reduced over-treatment. More recently, with colleagues from the TPCG, he has established a platform for Integrated Genomics and Clinical Profiling to explore the potential for targeted adjuvant therapies to improve primary cure rates in poor prognosis prostate cancer.
In the University of Cambridge, he leads the University Academic Urology Group and established the Cambridge Urology Translational Research and Clinical Trials office which has recruited >1600 patients to various NIHR and portfolio urology trials. He is also clinical directorate lead for urology research. He holds patents and has won numerous prizes for research, including the CE Alken prize, Urological Research Society Medial, Hunterian Professorship and is the recipient of a University of Cambridge Vice Chancellors Award for Research Impact (Established Researcher). He is also Visiting Professor at Anglia Ruskin University.
研究兴趣
论文共 297 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Dan J Woodcock, Atef Sahli, Ruxandra Teslo,Vinayak Bhandari,Andreas J Gruber, Aleksandra Ziubroniewicz,Gunes Gundem, Yaobo Xu,Adam Butler,Ezequiel Anokian,Bernard J Pope,Chol-Hee Jung,
Cell genomicsno. 3 (2024): 100511-100511
European urology oncology (2024)
Michael Wang, Jack Vercnocke,Kevin B. Ginsburg, Stephanie Daignault-Newton, Tudor Borza,Alice Semerjian,Vincent J. Gnanapragasam
Urologic Oncology: Seminars and Original Investigations (2024)
Michael Wang, Jack R. Vercnocke, Stephanie Diagnault-Newton, Corinne Labardee,Alice Semerjian,Tudor Borza,Vincent Gnanapragasam,Kevin Ginsburg
JAMA oncologyno. 11 (2023): 1514-1524
NEJM Evidenceno. 4 (2023): EVIDoa2300018-EVIDoa2300018
BJUI Compassno. 5 (2023): 501-503
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn